# IGC Pharma, Inc.

IGC Pharma, Inc. is an Asset Manager.

## Overview

- **Organization type:** Asset Manager
- **Assets under management:** Undisclosed
- **Website:** https://igcpharma.com
- **LinkedIn:** https://www.linkedin.com/company/igcpharma

## Regulatory record

- **Reports private funds:** No

## About

IGC Pharma, Inc. is a publicly traded pharmaceutical company (NYSE American: IGC) that develops therapeutics derived from cannabinoids. The firm was founded in 2005 and is headquartered in Maryland, though its operational history includes a shift from a broader cannabis strategy to a targeted CNS drug development pipeline. The underlying wealth originates from public shareholders, not a single family or fortune. The firm's primary focus is on IGC-AD1, a synthetic cannabinoid formulation in Phase 2 clinical trials for agitation in Alzheimer's disease (per company filings, 2023). It also maintains a pipeline of preclinical candidates targeting neuroinflammation and pain. IGC Pharma funds operations through equity offerings, including a $2.3 million registered direct offering closed in April 2024. As of 2025, the company had a market capitalization below $50 million and reported cash and equivalents of approximately $5.1 million in its most recent 10-Q filing. The firm employs fewer than 20 full-time staff, with a scientific advisory board including neurology specialists. It operates out of a single office in Rockville, Maryland. IGC Pharma's structural differentiator is its status as a publicly traded biotech with a THC-free synthetic cannabinoid platform — an unusual asset class for a micro-cap public company. The firm does not cultivate or distribute cannabis; it uses isolated synthetic analogs to pursue FDA approvals, a regulatory posture that separates it from the broader cannabis industry.

## Sectors

- Pharmaceuticals
- Biotechnology
- Healthcare

## Questions

### What is IGC Pharma's lead drug candidate?

IGC-AD1, a synthetic cannabinoid formulation in Phase 2 trials for agitation in Alzheimer's disease (per company filings, 2023).

### How is IGC Pharma structured as an investment vehicle?

It is a publicly traded company on the NYSE American under the ticker IGC, funded through equity offerings and not a family office or private fund.

### Does IGC Pharma cultivate or distribute cannabis?

No. The firm develops synthetic, THC-free cannabinoid analogs for pharmaceutical use and does not engage in cannabis cultivation or retail distribution.

### What is the firm's geographic footprint?

IGC Pharma operates from a single office in Rockville, Maryland, with clinical trial sites in the United States.

### Who manages the company?

The CEO is Ram Mukunda, who has led the company since its inception (per the firm's SEC filings and website). A scientific advisory board supports drug development.

### What are the primary risks for investors?

Key risks include clinical trial failure, regulatory hurdles with the FDA, and securing additional funding given the company's micro-cap status and limited cash reserves.

## Related profiles

- [Inception Growth Acquisition Ltd](https://altss.com/profile/inception-growth-acquisition-ltd)
- [PermRock Royalty Trust](https://altss.com/profile/permrock-royalty-trust)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/igc-pharma-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology